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Introduction
Aberrant DNA methylation is a common feature of malignant 
cells and, thus, the methylation status of key cell cycle regulation 
genes is often proposed as a reliable and sensitive early marker for 
breast cancer.1,2 Classic tumor suppressor genes and other regula-
tory genes are frequently silenced by methylation at their pro-
moter regions in cancerous breast tissue.3,4
Promising estimates for sensitivity and specificity for the detec-
tion of cancerous breast tissue have been observed using promoter 
methylation of a small panel of common cancer-related genes to 
discriminate between normal and diseased tissue. For example, 
Fackler and colleagues5 reported a sensitivity for detection of 
breast cancer of 85% and a specificity of 89% based on a panel of 
four genes (CCND2, HIN1, RASSF1 and TWIST ) in 18 normal 
mammoplasty and 21 tumor specimens. Similarly, Esteller and 
colleagues6 reported a sensitivity of 73% using a different panel of 
four genes (GSTP1, BRCA1, CDH1 and P16 ) based on 45 breast 
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cancer tumors. In another report by Fackler7 with five candidate 
genes evaluated, one or more methylated genes were detected in 
100% of invasive lobular cancer and 95% of lobular in situ tumors 
(total of 103 cases). Collectively, these data indicate that the pro-
moter methylation status of even a relatively small number of genes 
is sufficient to distinguish breast cancer tissue from normal tissue.
Other data indicate that higher levels of DNA, as much as six 
times higher on average, can be detected in the blood of breast 
cancer cases than in the blood of healthy subjects.8 Furthermore, 
DNA from plasma or serum from breast cancer patients has been 
suggested to be of tumor origin because in several small studies 
the promoter methylation patterns in serum or plasma DNA have 
shown high concordance to those found in corresponding tumors.9 
However, the proportion of free circulating DNA that is from the 
tumor has been reported to vary widely, from less than 0.5% to 
90%.10,11 This variability and other technical issues have led some 
researchers to question the feasibility of developing a circulating 
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from postmenopausal women in three study groups: breast can-
cer cases with lymph node-positive disease (n = 241), breast can-
cer cases with lymph node-negative disease (n = 63) and benign 
breast disease control subjects (n = 234). A description of selected 
baseline characteristics for women in each of the study groups 
is presented in Table 1. Overall, the mean age at blood collec-
tion was 63.0 y: SD 9.9; range 35–91. On average, lymph node-
positive and negative breast cancer cases were six to seven years 
older than the benign breast disease controls. Lymph-node posi-
tive breast cancer cases also tended to be slightly more likely to be 
nulliparous (18.3 vs 15.8%), to have a later age at first birth (24.2 
vs 23.2 y), to have a later age at menopause (47.3 vs 45.7 y) and 
to have a family history of breast cancer (26.7% vs 24.0%) than 
benign breast disease controls. Compared with benign breast 
disease control subjects, lymph node-negative breast cancer cases 
were also more likely to be nulliparous (24.4% vs. 15.8%), to 
have a later age at first birth (25.0 vs. 23.2 y), to have a family his-
tory of breast cancer (33.9% vs. 24.0%), and to have a later age 
at menopause (46.6 vs. 45.7 y). However, lymph node-positive 
breast cancer cases were more likely to have ever smoked than 
benign breast disease controls (41.0% vs. 33.0%) whereas lymph 
node-negative cases were less likely to have ever smoked (19.1% 
vs. 33.0%). The three study groups were very similar in other fac-
tors, including age at menarche, body mass index, and number of 
full-term pregnancies.
Comparison of median levels of gene promoter methyla-
tion across the three groups. Pyrosequencing analysis was used 
to assess the percent of DNA that was methylated at specific 
CpG sites in the promoter regions of 12 genes. The average of 
the percent methylation over all the promoter CpG sites for each 
gene (ranging from 3 to 27 CpG sites per gene) was calculated. 
Median levels of the average DNA methylation for 12 genes for 
each of the three study groups and the corresponding 10th to 
90th percentiles are presented in Table 2. Overall, median levels 
of promoter methylation were very low, typically below 5%, for 
each gene in all of the study groups. For all of the 12 genes, as 
hypothesized, median levels of methylation were slightly higher 
in breast cancer cases with positive lymph nodes than in benign 
breast disease control subjects (by 3.3% for RASSF1 to 47.7% for 
have directly assessed the ability of promoter methylation status, 
typically in one to four genes, in serum or plasma DNA to dis-
criminate between breast cancer cases and controls.14 For example, 
Hoque and colleagues15 reported a sensitivity of 62% and specificity 
of 85% with four candidate genes (APC, GSTP1, RASSF1A and 
RARβ2) using quantitative methylation-specific PCR (QMSP) in a 
study of 47 breast cancer cases and 38 control subjects. By contrast, 
a recently published larger study by Brooks and colleagues16 was not 
successful in distinguishing between 50 breast cancer cases and 300 
cancer-free controls based on the methylation status via QMSP of 
same four genes that were studied by Hoque and colleagues.15 Based 
on a re-analysis of a subset of specimens using quantitative pyrose-
quencing, Brooks and colleagues16 attributed their inability to detect 
differences in promoter methylation status between cases and con-
trols to a high prevalence of false-positives using QMSP methods 
on serum DNA. In contrast to QMSP, pyrosequencing allows for 
the interrogation of the methylation status of multiple CpG sites, 
and has an internal control to test for complete bisulfite treatment.
Thus, the objective of the present study was to evaluate whether 
an expanded panel of 12 tumor suppressor genes (APC, BRCA1, 
CDH1, CCND2, ESR1, GSTP1, HIN1, p16, RASSF1, RARβ, 
SFRP1 and TWIST1) frequently found to be methylated in breast 
cancers but not in normal breast tissue, when combined with the 
quantitative pyrosequencing methods to assess promoter methyla-
tion status, would lead to a sufficiently sensitive and specific serum-
based methylation marker. We analyzed promoter methylation in 
DNA from serum collected at the time of diagnosis from 325 breast 
cancer cases and 249 benign breast disease controls who donated 
blood from 1977 to 1987 to the Mayo Serum Bank, a resource estab-
lished to identify new early markers of breast cancer. We examined 
promoter methylation in DNA from serum from lymph-node posi-
tive and lymph-node negative breast cancer cases separately based 
on reports that the methylation pattern of tumor suppressor genes 
may be associated with the clinical characteristics of the tumor.17
Results
Characteristics of study participants. This study compared the 
promoter methylation status of 12 genes in serum DNA obtained 
Table 1. selected characteristics of the study population
Characteristic
BBD controls  
(n = 234)
BC cases negative nodes  
(n = 63)
BC cases positive nodesd  
(n = 241)
age at blood collection; mean (s.D.) in years 59.3 (9.1) 67.0 (8.4) 65.4 (10.1)
age at menarche; mean (s.D.) in yearsa 13.0 (1.7) 13.3 (1.7) 13.1 (1.4)
age at menopause; mean (s.D.) in years 45.7 (6.9) 46.6 (6.5) 47.3 (5.6)
Body mass index (kg/m2)b 24.9 (3.7) 25.6 (4.2) 25.7 (4.6)
Nulliparous (%) 15.8% 25.4% 18.3%
No. of full-term pregnancies 3.2 (1.6) 2.9 (1.8) 3.2 (1.8)
age at first full-term pregnancy; mean (s.D.) in years 23.2 (4.5) 25.0 (5.3) 24.2 (4.8)
Family history of breast cancer (%)c 24.0% 33.9% 26.7%
Ever smoked (%) 33.0% 19.1% 41.0%
aUnknown for 5 controls, 0 node-negative, and 2 node-positive cases; bunknown for 1 control, 0 node-negative and 1 node-positive cases; cunknown 
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q = 0.43), SFRP1 (p = 0.16, q = 0.43), ESR1 (p = 0.17, q = 0.43), P16 
(p = 0.19, q = 0.43), APC (p = 0.19, q = 0.43) and HIN1 (p = 0.21, 
q = 0.43). Odds ratios and 95% confidence intervals compar-
ing the three highest quartiles to lowest quartile of gene meth-
ylation for lymph node-positive breast cancer cases compared 
with benign breast disease controls are also shown. For APC and 
TWIST, the odds ratios comparing the highest to lowest quartiles 
were elevated and marginally statistically significant. Specifically, 
the OR comparing the highest to lowest quartile of gene meth-
ylation for TWIST was 1.75 (95% CI = 1.0–3.0). The compa-
rable figure for APC was 1.78 (95% CI = 1.0–3.0). For ESR1 and 
SFRP1, the odds ratios in the top three quartiles compared with 
the lowest quartile all tended to be elevated; only the top quar-
tile for ESR was marginally statistically significant (RR = 1.77; 
95% CI = 1.0–3.1). For two of the remaining genes (BRCA1 and 
CCND2), the highest odds ratio was also observed in the top 
quartile.
Results were generally similar when we examined each gene 
separately among women with 1–2 and 3+ positive nodes com-
pared with benign breast disease controls. For example, the 
three most statistically significant genes after adjustment for the 
Q-value were TWIST, SFRP1 and ESR1 for women with 1–2 
SFRP1). In addition, in seven of the 12 genes (BRAC1, CCND2, 
CDH1, ESR1, HIN1, P16 and TWIST ), the median methyla-
tion level was also higher in breast cancer cases with negative 
lymph nodes than in benign breast disease subjects. In four genes 
(CCND2, HIN1, P16 and TWIST ), median levels of methylation 
were highest in lymph-node positive breast cancer cases, interme-
diate in the lymph-node negative breast cancer cases and lowest in 
benign breast disease control subjects. Median levels of the aver-
age DNA methylation for 12 genes were also examined by two 
categories of number of positive nodes (1–2 vs 3+) among the 
159 node-positive cases only. In eight of the 12 genes, the median 
methylation levels were slightly higher in cases with 3+ positive 
nodes than in cases with 1 or 2 positive nodes, although this dif-
ference was statistically significant only for ESR1 (2.7% vs 2.0%).
Comparison of quartile levels of gene promoter methylation 
between lymph node-positive breast cancer cases and benign 
breast disease controls. The distribution of lymph node-positive 
breast cancer cases in each quartile of gene methylation (quar-
tile cut points were based on the distribution of gene methyla-
tion in benign breast disease controls) is presented in Table 3. 
The six most statistically significant findings, after adjustment 
of the false-positive rate (q-value), were for TWIST (p = 0.04, 
Table 2. Median methylation levels (average over all cpG sites per gene) by case-control status
 [# CpG sites]
BBD controls (n = 234) BC cases negative nodes (n = 63) BC cases positive nodesa (n = 241)





































































































































Table 3. association between quartile levels of mean methylation scores and node-positive breast cancer
BBD controls  
N %
BC cases positive nodesb 
N %
BC cases positive nodesb 
OR (95% CI)
p (q)
APC (%) 0.19 (0.43)
Q1 ≤ 0.4 51 (25.8) 38 (20.0) 1.0a
Q2 (0.4–0.7) 49 (24.7) 41 (21.6) 1.12 (0.6–2.0)
Q3 (0.7–1.0) 49 (24.7) 46 (24.2) 1.26 (0.7–2.3)
Q4 (1.0–39.6) 49 (24.7) 65 (34.2) 1.78 (1.0–3.1)
BRCA1 (%) 0.44 (0.75)
Q1 ≤ 1.2 37 (25.2) 34 (21.5) 1.0a
Q2 (1.3–3.2) 37 (25.2) 34 (21.5) 1.00 (0.5–1.9)
Q3 (3.2–4.1) 36 (24.5) 37 (23.4) 1.12 (0.6–2.2)
Q4 (4.1–35.6) 37 (25.2) 53 (33.5) 1.56 (0.8–2.9)
CCND2 (%) 0.56 (0.84)
Q1 ≤ 0.9 43 (25.1) 38 (21.3) 1.0a
Q2 (0.9–1.5) 44 (25.7) 48 (27.0) 1.23 (0.7–2.2)
Q3 (1.5–2.4) 42 (24.6) 38 (21.3) 1.02 (0.6–1.9)
Q4 (2.4 -32.9) 42 (24.6) 54 (30.3) 1.46 (0.8–2.6)
CDH1 (%) 0.83 (0.94)
Q1 ≤ 1.0 48 (25.1) 44 (22.0) 1.0a
Q2 (1.0–2.3) 48 (25.1) 57 (28.5) 1.30 (0.7–2.3)
Q3 (2.3–4.6) 47 (24.6) 47 (23.5) 1.09 (0.6–1.9)
Q4 (4.6–46.9) 48 (25.1) 52 (26.0) 1.18 (0.7–2.1)
ESR1 (%) 0.17 (0.43)
Q1 ≤ 1.3 53 (25.0) 35 (17.5) 1.0a
Q2 (1.3–2.1) 53 (25.0) 58 (29.0) 1.66 (0.9–2.9)
Q3 (2.1–3.7) 53 (25.0) 45 (22.5) 1.29 (0.7–2.3)
Q4 (3.7–95.4) 53 (25.0) 62 (31.0) 1.77 (1.0–3.1)
GSTP1 (%) 0.86 (0.94)
Q1 ≤ 0.9 47 (25.3) 41 (23.0) 1.0a
Q2 (0.9–1.3) 48 (25.8) 42 (23.6) 1.00 (0.6–1.8)
Q3 (1.3–1.8) 44 (23.7) 47 (26.4) 1.23 (0.7–2.2)
Q4 (1.8–50.0) 47 (25.3) 48 (27.0) 1.17 (0.7–2.1)
HIN1 (%) 0.21 (0.43)
Q1 ≤ 0.7 33 (25.2) 36 (25.5) 1.0a
Q2 (0.7–1.0) 33 (25.2) 31 (22.0) 0.86 (0.4–1.7)
Q3 (1.0–2.0) 32 (24.4) 24 (17.0) 1.70 (0.3–1.4)
Q4 (2.0–24.2) 33 (25.2) 50 (35.5) 1.39 (0.7–2.6)
P16 (%) 0.19 (0.43)
Q1 ≤ 0.6 48 (25.4) 48 (24.9) 1.0a
Q2 (0.6–1.0) 47 (24.9) 33 (17.1) 0.70 (0.4–1.3)
Q3 (1.0–2.5) 47 (24.9) 63 (32.6) 1.34 (0.8–2.3)
Q4 (2.5–39.9) 47 (24.9) 49 (25.4) 1.04 (0.6–1.8)
RARβ (%) 0.94 (0.94)
Q1 ≤ 0.8 58 (26.1) 61 (27.4) 1.0a
Q2 (0.8–1.2) 60 (27.0) 60 (26.9) 0.95 (0.6–1.6)
Q3 (1.2–1.7) 48 (21.6) 43 (19.3) 0.85 (0.5–1.6)
Q4 (1.7–14.2) 56 (25.2) 59 (26.5) 1.00 (0.6–1.7)
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disease control subjects but there were no statistically significant 
differences.
We also considered the extent to which the methylation 
pattern in a combination of genes could distinguish between 
breast cancer cases from control subjects. The Random Forests 
statistical algorithm was applied to assess the discriminating 
ability of the multiple gene panel of DNA methylation profiles 
in distinguishing the node-positive cases from the controls.18 
Genes with greater than 25% of subjects missing methylation 
values (CCND2, HIN1 and BRAC1) were excluded from the 
analysis. Subjects missing any values for the remaining nine 
genes were excluded—this resulted in the inclusion of 103 con-
trols and 97 node-positive cases in the analysis. The out of bag 
error rate of the Random Forests classifier in predicting case/
control status was 0.45, with a corresponding area under the 
curve (AUC) estimate of 0.45. A permutation test of the statis-
tical significance of this classifier when compared with random 
chance resulted in a p value of 0.15. These results from the 
Random Forests classifier trained on methylation profiles cor-
responding to the panel of nine genes indicate no significant 
improvement in predictive power when compared with random 
chance.
Discussion
We conducted a case-control study to examine the extent to 
which promoter methylation of 12 breast cancer-related genes 
could serve as a marker for the early detection of breast cancer. 
To our knowledge, this is the first such study to use pyrosequenc-
ing to detect DNA methylation of cancer-related genes in serum. 
Serum was obtained from women who donated blood to the 
Mayo Serum Bank during 1977 to 1987 prior to undergoing a 
breast biopsy or mastectomy. We selected a panel of 12 tumor 
positive nodes and ESR1, APC and TWIST for women with 3 
or more positive nodes. Finally, risk estimates presented in Table 
4 for node-positive breast cancer cases did not change meaning-
fully after adjustment for age at blood collection.
Comparison of quartile levels of gene methylation between 
lymph-node negative breast cancer cases and benign breast dis-
ease controls. The distribution of lymph-node negative breast 
cancer cases in each quartile of gene methylation (quartile cut-
points were based on the distribution of gene methylation in 
benign breast disease controls) is presented in Table 4. Odds 
ratios and 95% confidence intervals comparing the three highest 
quartiles to lowest quartile of gene methylation for lymph-node 
negative breast cancer cases compared with benign breast dis-
ease controls are also shown. The two most statistically signifi-
cant findings, after adjustment of the false-positive rate (q-value), 
were for TWIST (p = 0.04) and HIN1 (p = 0.003). Finally, risk 
estimates presented in Table 4 for node-negative breast cancer 
cases did not change meaningfully after adjustment for age at 
blood collection
Comparison of gene methylation levels of 5% or higher 
across study groups. Table 5 presents the distribution of women 
in each of the three study groups with a methylation level of at 
least five percent for specific genes. The proportion of individuals 
with ≥ 5% methylation was higher in lymph-node positive breast 
cancer cases than in benign breast disease control subjects for ten 
of 12 genes. However, for only two genes, HIN1 and TWIST, 
was the proportion of subjects with methylation scores of 5% 
or greater statistically significantly higher in the node-positive 
breast cancer cases as compared with controls (22.0% vs 12.2%, 
p = 0.04; 37.9% vs 24.5%, p = 0.004, respectively). For all but 
four genes (APC, GSTP1 P16 and SFRP1), the proportion of 
individuals with mean methylation scores of ≥ 5% was higher in 
lymph-node-negative breast cancer cases than in benign breast 
Table 3. association between quartile levels of mean methylation scores and node-positive breast cancer
BBD controls  
N %
BC cases positive nodesb 
N %
BC cases positive nodesb  
OR (95% CI)
p (q)
RASSF1 (%) 0.73 (0.94)
Q1 ≤ 1.1 51 (25.5) 42 (21.9) 1.0a
Q2 (1.1–1.7) 49 (24.5) 49 (25.5) 1.21 (0.7–2.2)
Q3 (1.7–2.9) 50 (25.0) 56 (29.2) 1.02 (0.8–2.4)
Q4 (2.9–68.2) 50 (25.0) 45 (23.4) 1.09 (0.6–1.9)
SFRP1 (%)
Q1 ≤ 0.6 46 (25.0) 35 (17.8) 1.0a 0.16 (0.43)
Q2 (0.6–1.1) 46 (25.0) 42 (21.3) 1.20 (0.7–2.2)
Q3 (1.1–4.5) 46 (25.0) 64 (32.5) 1.83 (1.0–3.3)
Q4 (4.5–64.5) 46 (25.0) 56 (28.4) 1.60 (0.9–2.9)
TWIST (%) 0.04 (0.43)
Q1 ≤ 2.3 50 (25.0) 44 (21.7) 1.0a
Q2 (2.3–3.5) 51 (25.5) 45 (22.2) 1.0 (0.6–1.8)
Q3 (3.5–4.9) 49 (24.5) 37 (18.2) 0.86 (0.5–1.5)
Q4 (4.9 -15.4) 50 (25.0) 77 (37.9) 1.75 (1.0–3.0)

























Table 4. association between quartile levels of mean methylation scores and node-negative breast cancer
BBD controls  
N %
BC cases negative nodes  
N %
BC cases negative nodes  
OR (95% CI)
p (q)
APC (%) 0.65 (0.45)
Q1 ≤ 0.4 51 (25.8) 16 (28.6) 1.0a
Q2 (0.4–0.7) 49 (24.7) 10 (17.9) 0.65 (0.3–1.6)
Q3 (0.7–1.0) 49 (24.7) 17 (30.4) 1.11 (0.7–2.3)
Q4 (1.0–39.6) 49 (24.7) 13 (23.2) 1.78 (1.0–3.1)
BRCA1 (%) 0.86 (0.49)
Q1 ≤ 1.2 37 (25.2) 8 (23.5) 1.0a
Q2 (1.3–3.2) 37 (25.2) 8 (23.5) 1.00 (0.3–2.9)
Q3 (3.2–4.1) 36 (24.5) 7 (20.6) 0.90 (0.3–2.7)
Q4 (4.1–35.6) 37 (25.2) 11 (32.4) 1.38 (0.5–3.8)
CCND2 (%) 0.50 (0.43)
Q1 ≤ 0.9 43 (25.1) 8 (15.7) 1.0a
Q2 (0.9–1.5) 44 (25.7) 13 (25.5) 1.59 (0.6–4.2)
Q3 (1.5–2.4) 42 (24.6) 15 (29.4) 1.92 (0.6–1.9)
Q4 (2.4 -32.9) 42 (24.6) 15 (29.4) 1.46 (0.8–2.6)
CDH1 (%) 0.10 (0.17)
Q1 ≤ 1.0 48 (25.1) 9 (17.6) 1.0a
Q2 (1.0–2.3) 48 (25.1) 9 (17.6) 1.00 (0.4–2.7)
Q3 (2.3–4.6) 47 (24.6) 11 (21.6) 1.25 (0.5–3.3)
Q4 (4.6–46.9) 48 (25.1) 21 (43.1) 2.44 (1.0–5.9)
ESR1 (%) 0.10 (0.17)
Q1 ≤ 1.3 53 (25.0) 10 (16.9) 1.0a
Q2 (1.3–2.1) 53 (25.0) 18 (30.5) 1.80 (0.8–4.3)
Q3 (2.1–3.7) 53 (25.0) 9 (15.3) 0.90 (0.3–2.4)
Q4 (3.7–95.4) 53 (25.0) 22 (37.3) 2.20 (1.0–5.1)
GSTP1 (%) 0.30 (0.41)
Q1 ≤ 0.9 47 (25.3) 14 (25.5) 1.0a
Q2 (0.9–1.3) 48 (25.8) 21 (38.2) 1.47 (0.7–3.2)
Q3 (1.3–1.8) 44 (23.7) 10 (18.2) 0.76 (0.3–1.8)
Q4 (1.8–50.0) 47 (25.3) 10 (18.2) 0.71 (0.3–1.8)
HIN1 (%) 0.003 (0.02)
Q1 ≤ 0.7 33 (25.2) 8 (22.2) 1.0a
Q2 (0.7–1.0) 33 (25.2) 10 (27.8) 1.25 (0.4–3.6)
Q3 (1.0–2.0) 32 (24.4) 1 (2.8) 0.13 (0.0–1.1)
Q4 (2.0–24.2) 33 (25.2) 17 (47.2) 2.13 (0.8–5.6)
P16 (%) 0.41 (0.43)
Q1 ≤ 0.6 48 (25.4) 13 (24.5) 1.01
Q2 (0.6–1.0) 47 (24.9) 8 (15.1) 0.63 (0.2–1.7)
Q3 (1.0–2.5) 47 (24.9) 15 (28.3) 1.18 (0.5–2.7)
Q4 (2.5–39.9) 47 (24.9) 17 (32.1) 1.34 (0.6–3.1)
RARβ (%) 0.65 (0.45)
Q1 ≤ 0.8 58 (26.1) 12 (20.0) 1.0a
Q2 (0.8–1.2) 60 (27.0) 16 (26.7) 1.29 (0.6–3.0)
Q3 (1.2–1.7) 48 (21.6) 17 (28.3) 1.71 (0.7–3.9)
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individuals with ≥ 5% methylation to be higher in lymph-node 
positive breast cancer cases than in benign breast disease control 
subjects for 10 of 12 genes. Despite the modestly higher methyla-
tion patterns we observed in cases compared with controls, our 
ability to discriminate between cases and controls was no better 
than random chance.
As reviewed by others,14,19 a number of studies using primar-
ily methyl-specific PCR or MethylLight assays have reported 
an association between serum DNA promoter methylation and 
breast cancer. However, most of these studies have had a small 
sample size, several have not included a control group, and the 
sensitivity estimates for individual genes have varied widely. 
Among the larger studies, Hoque and colleagues15 reported a sen-
sitivity of 62% and specificity of 87% with four candidate genes 
suppressor genes (APC, BRCA1, CDH1, CCND2, ESR1, GSTP1, 
HIN1, p16, RASSF1, RARβ, SFRP1 and TWIST1) frequently 
found to be methylated in breast cancers but not in normal 
breast tissue,3 including several genes that have been observed to 
be methylated in the serum of breast cancer patients.15 We found 
evidence that median levels of promoter methylation in serum 
DNA were modestly higher in breast cancer cases than benign 
breast disease controls, and higher in node-positive breast can-
cer cases than in node-negative cases. Further, analyses focused 
on the distribution of lymph node-positive cases vs. benign 
breast disease controls in each quartile level of gene promoter 
methylation found the most statistically significant results for 
TWIST, SFRP, ESR1, P16, APC and HIN1 with p values ranging 
between 0.04 and 0.21. Additionally, we found the proportion of 
Table 4. association between quartile levels of mean methylation scores and node-negative breast cancer
BBD controls  
N %
BC cases negative nodes  
N %
BC cases negative nodes  
OR (95% CI)
p (q)
RASSF1 (%) 0.86 (0.49)
Q1 ≤ 1.1 51 (25.5) 11 (22.0) 1.0a
Q2 (1.1–1.7) 49 (24.5) 13 (26.0) 1.00 (0.3–2.9)
Q3 (1.7–2.9) 50 (25.0) 15 (30.0) 0.90 (0.6–3.3)
Q4 (2.9–68.2) 50 (25.0) 11 (22.0) 1.02 (0.4–2.6)
SFRP1 (%) 0.47 (0.43)
Q1 ≤ 0.6 46 (25.0) 10 (18.9) 1.0a
Q2 (0.6–1.1) 46 (25.0) 12 (22.6) 1.20 (0.5–3.1)
Q3 (1.1–4.5) 46 (25.0) 19 (35.8) 1.90 (0.8–4.5)
Q4 (4.5–64.5) 46 (25.0) 12 (22.6) 1.20 (0.5–3.1)
TWIST (%) 0.04 (0.14)
Q1 ≤ 2.3 50 (25.0) 5 (8.9) 1.0a
Q2 (2.3–3.5) 51 (25.5) 19 (33.9) 3.73 (1.3–10.7)
Q3 (3.5–4.9) 49 (24.5) 14 (25.0) 2.86 (1.0–8.5)
Q4 (4.9 -15.4) 50 (25.0) 18 (32.1) 3.60 (1.2–10.4)
aReference category.
Table 5. Number and percent of study subjects with mean methylation scores of 5% or more for each gene among the three study groups
BBD controls BC cases negative nodes BC cases positive nodesa
N % N % n % pb
apc 10 5.1 1 1.8 8 4.2 0.81
BRca1 31 21.1 10 29.4 46 29.1 0.12
ccND2 11 6.4 4 7.8 20 11.2 0.13
cDh1 41 21.5 20 39.2 48 24.0 0.63
EsR1 48 22.6 18 30.5 52 26.0 0.49
GsTp1 11 5.9 3 5.5 17 9.6 0.24
hIN1 16 12.2 6 16.7 31 22.0 0.04
p16 29 15.3 6 11.3 33 17.1 0.68
RaRβ 7 3.2 2 3.3 7 3.1 1.0
RassF1 18 9.0 8 16.0 21 10.9 0.61
sFRp1 41 22.3 11 20.8 51 25.9 0.47
TWIsT 49 24.5 18 32.1 71 37.9 0.004

























Furthermore, many of these genes have also been shown in sev-
eral small studies to be more frequently methylated in the serum 
of breast cancer cases than that of controls.14,15
A special aspect in our study that deserves additional consid-
eration is that all of the controls had a prior breast biopsy with 
evidence of benign breast disease. Some limited evidence indi-
cates that increased DNA methylation of some tumor suppressor 
genes is detectable in benign breast disease.22 The types of benign 
breast disease included in our study have only been minimally 
associated with breast cancer.23 The large, well-matched control 
group is a strength of our study. If it were in fact true that our 
generally null findings reflect our choice of women with benign 
breast disease as controls, our findings would still imply that this 
panel of genes would not be useful in a clinical setting because 
benign breast disease is a common condition.
In summary, we were able to detect modest differences in pro-
moter methylation in serum DNA in breast cancer cases and con-
trols. Our findings and those of the recent study by Brooks and 
colleagues16 emphasize the need to demonstrate the reliability 
and validity of the methods being proposed to measure low levels 
of promoter methylation in the small quantities of tumor-derived 
DNA in circulation, as well as the need to design sufficiently 
sized prospective studies with well-selected control groups.
Materials and Methods
Between 1977 and 1987, all patients about to undergo breast 
biopsy or mastectomy in three hospitals in Grand Rapids, 
Michigan were invited to provide serum as part of a study to 
assess new putative breast cancer markers. Participants provided 
written informed consent and completed an in-person interview 
assessing breast cancer risk factors. Information on pathology and 
extent of disease was abstracted from medical records. Serum 
was collected prior to the day of surgery or on the day of surgery 
for all study subjects. Before surgery, 5,358 volunteers donated 
20 mL of non-fasting blood that was collected in sterile vacu-
tainers, immediately chilled, and allowed to clot. The serum was 
separated within two hours and then divided into 1 mL aliquots 
and stored at -70°C in sealed glass vials. Specimens were then 
shipped frozen, in containers with dry ice, first to a central reposi-
tory at the Mayo Foundation and subsequently to the National 
Cancer Institute and stored at -70°C to -85°C at both locations.24
For the present study, eligible women were postmenopausal, 
had no prior cancer or diabetes, and were not currently using 
hormone replacement therapy or oral contraceptives at the time 
of the blood draw. In addition, individuals had to have 2 mL 
or more of serum remaining in the bank. A total of 325 breast 
cancer cases (69 node-negative breast cancer cases and 256 pri-
marily node positive breast cancer cases) and 249 control sub-
jects were selected for this study. The mean time from the date 
of malignant diagnosis and blood collection was 0.46 d (95% 
CI: -0.7, 1.6) for node-negative cases and 0.4 d (95% CI: -3.0, 
3.9) for node-positive cases. Because the cases were diagnosed in 
the 1970s, data on estrogen receptor, progesterone receptor and 
HER2/neu receptor status were not available. Control subjects 
had benign breast disease conditions that have been linked to no 
(APC, GSTP1, RASSF1A and RARβ2) using quantitative meth-
ylation-specific PCR (QMSP) in a study of 47 breast cancer cases 
and 38 control subjects. In this study, Hoque and colleagues15 
reported that only 13% of the controls had methylation in any of 
these four tumor-related genes. By contrast, a more recent study 
by the same group20 reported that nearly 50% of 157 cancer-free 
individuals had one or more of six tumor-related genes (APC, 
GSTP1, RARβ2, CCND2, MGMT and P16 ) methylated in 
serum using QMSP, including 22% in RARβ2 alone. These lat-
ter two studies highlight the variability in percent methylation 
in serum DNA in patients and controls that has been observed 
across studies. A recent case-control study nested within a pro-
spective cohort by Brooks and colleagues found no ability to dis-
criminate breast cancer cases diagnosed in the prior six months 
(n = 50) from control subjects (n = 150) using the same gene 
panel as Hoque and colleagues.15,16 The authors found that the 
methylation levels in breast cancer cases were less than expected 
but methylation levels in control subjects were higher than 
expected. Brooks and colleagues16 utilized quantitative methyla-
tion specific PCR (QMSP) for the main analysis but reanalyzed 
a small subset of samples using pyrosequencing. Because pyrose-
quencing frequently did not confirm their methylation results as 
detected by QMSP, Brooks and colleagues16 concluded that their 
main analysis contained a substantial number of false positives. 
Further, the overall null findings were attributed to non-specific 
amplification resulting in high-false positives, and the false nega-
tives to the low amount of DNA template. In the present study, 
we employed pyrosequencing to examine methylation in serum 
in 12 genes yet still did not find any significant predictive ability 
based on methylation patterns.
There are several potential explanations for the low predic-
tive ability we observed in our study. The first and most likely 
explanation is the lack of precision of the pyrosequencing assays. 
Indeed, the coefficients of variation (CVs) for the 0% methyl-
ation control sample across plates were poor, and even for the 
50% methylation control sample we had less than desired CVs 
(8.5–34%).
Another potential explanation for the limited predictive power 
we observed is that the quality and/or quantity of the DNA in 
the samples could have been insufficient for accurately measuring 
methylation. For most of the genes we examined, however, the 
pyrosequencing pass rate ranged from 70% to 94%, suggesting 
that the DNA obtained was adequate for PCR amplification and 
sequencing. Still, the proportion of tumor DNA in serum may 
be too low to be detected reliably by pyrosequencing of bisulfite-
modified DNA.12,13 Zanetti-Dallenbach and colleagues21 recently 
demonstrated that the amount of shed DNA in serum is ten times 
higher than in plasma, likely due to leaked white blood cells dur-
ing the coagulation that occurs in the collection of serum. Thus, 
in the present analysis, white blood cell DNA could have diluted 
the methylation signal of the shed tumor DNA in serum.
Although it is also possible that promoter methylation status 
of another set of genes might more clearly distinguish between 
breast cancer cases and controls, the panel we selected was 
based on prior evidence that the included genes are frequently 
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the 50% DNA methylated sample was 27% (8.5–34%). Lastly, 
among the replicates of the 100% DNA methylated sample, the 
median (range) of CV was 3.9% (0.68–19%). For all genes, the 
replicate measurements of the 100% methylated sample resulted 
in the lowest CV.
Statistical analysis. Evaluation of the association between 
case-control status and the percent of subjects in each quartile 
of mean methylation levels for each gene was based on logistic 
regression models. Two separate sets of analyses were conducted 
to compare (1) the controls to the node-positive subjects and (2) 
the controls to the node-negative subjects. The mean methyla-
tion levels across the CpG sites in each gene were categorized into 
quartiles based on the distribution in the control subjects. Two-
sided p values were calculated based on likelihood ratio tests. 
Univariate models as well as multivariable models adjusted for 
age were fit.
As several genes were evaluated in this study, adjustment for 
multiple comparisons was performed based on the q value proce-
dure.25 If all genes below a specific p value threshold are denoted 
as “true markers,” the associated q value provides a measure of the 
proportion of false discoveries. This procedure is less conservative 
than traditional methods, such as the Bonferroni correction, and 
is more powerful in detecting true associations.
A multivariable analysis assessing the predictive power of the 
panel of genes was conducted using the Random Forests algo-
rithm.18 The classifier was trained by setting the number of trees 
to 10,000 and by considering a random subset of three genes at 
each split of every tree. The predictive power of the panel of genes 
was assessed based on the proportion of subjects that were cor-
rectly classified as cases or controls, among samples left out of the 
training process (out of bag samples). The predictive power of the 
panel of genes was assessed based on the proportion of subjects 
that were correctly classified as cases or controls (i.e., sensitivity 
and specificity) among samples left out of the training process 
(out of bag samples). A p value denoting the statistical signifi-
cance of the Random Forests classifier was calculated by a per-
mutation test—the subjects’ case/control labels were randomly 
permuted 100 times and the distribution of the out of bag error 
rate was estimated. The p value corresponding to the Random 
Forests classifier was calculated as the proportion of random per-
mutations in which the out of bag error rate was equal to or lower 
than the observed out-of-bag error rate.
Box plots showing the distribution of mean percent methyla-
tion levels for each of the 12 genes among the control, node-nega-
tive and node-positive subjects are included in the Supplemental 
Material. The lines at the bottom, middle and top of each 
box denote the 25th, 50th (median) and 75th percentiles of 
each distribution. Circles represent outliers in both tails of the 
distribution.
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or minimally increased risk of breast cancer.23 Benign conditions 
included 71 women with non-proliferative benign changes (e.g., 
atrophic lobules, apocrine metaplasia) and 178 women who had 
low-risk proliferative conditions (e.g., cysts, fibroadenoma and 
mild hyperplasia).
Analysis of DNA methylation. DNA methylation analyses 
were conducted by EpigenDX Inc. Serum specimens were shipped 
on dry ice from the National Cancer Institute to EpigenDX Inc. 
The laboratory was blinded as to case-control status of the study 
subjects. DNA was extracted from 500 μL of serum and eluted 
in 30 μL of buffer; estimated to contain between 10 to 50 ng of 
DNA all of which was modified with bisulfite treatment (during 
which unmethylated cytosines are converted to uracil) and eluted 
in 18 to 20 μL of buffer. One microliter of bisulfite-modified 
DNA was used for each gene-specific amplification and 10 μl of 
the PCR products were sequenced by Pyrosequencing PSQ96 HS 
System (Qiagen). If the pyrosequencing failed due to low signal, 
a nested PCR reaction was done using the DNA from the ini-
tial PCR reaction and a second pyrosequencing was conducted. 
The methylation status of each locus (see Table 2 for number 
of CpG sites per gene) was analyzed individually as a T/C SNP 
using QCpG software (Qiagen). Resulting pyrograms and per-
cent methylation scores for each CpG site were received from 
EpigenDX, Inc. Each pyrogram was visually inspected for quality 
controls including bisulfite-conversion, expected sequence order 
and peak height. Data from only those pyrograms that passed 
all quality controls were included in the analyses. The pass rate 
ranged from 70% to 94%.
For the methylation analysis of each gene, serum samples 
from cases and control subjects were arranged randomly on eight 
96-well plates (the same order of cases and controls for each gene). 
Due to technical laboratory issues, 36 study subjects on the first 
plate for each gene were omitted from all analyses. Thus, the final 
sample size consisted of 304 breast cancer cases (241 with pri-
marily node-positive and 63 with node-negative disease) and 234 
control subjects. Of the 241 primarily node-positive cases, 159 
had at least one documented positive node, and the node status 
on the remaining 82 breast cancer cases was uncertain. Thus, 
the node-positive group may include some individuals who were 
node-negative. The mean time between the original date of blood 
collection and the methylation analysis was 29.4, 28.2 and 28.8 y 
for node-positive breast cancer cases, node negative breast cancer 
cases, and control subjects, respectively.
The number of CpG sites interrogated per gene varied from 
a low of 3 for RARβ to a high of 27 for HIN1. As displayed in 
Table 2, the percentage of subjects with available gene methyla-
tion data ranged from a low of 51.1, 58.5, and 56.0% for HIN1 to 
88.9, 92.5 and 94.9% for RARβ for node-positive breast cancer 
cases, node-negative breast cancer cases and benign breast disease 
control subjects, respectively.
As part of the quality control procedure, 0%, 50% and 100% 
methylated DNA samples (provided by the laboratory) were 
included on each plate. The median (range) of the gene-specific 
coefficient of variation (CV) among the replicate measurements 
of the 0% methylated DNA sample was 52.5% (12–139%). The 
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